MHB036C + MHB039A

MHB036C + MHB039A is a combination therapy consisting of two investigational agents developed by Minghui Pharmaceutical for advanced solid tumors, particularly non-small cell lung cancer (NSCLC) and breast cancer. MHB036C is a TROP-2–targeted antibody-drug conjugate (ADC) built using Minghui's proprietary SuperTopoi ADC platform and features a humanized anti–TROP-2 monoclonal antibody conjugated to a potent DNA topoisomerase I inhibitor via a cleavable linker[2][1]. MHB039A is a bispecific antibody simultaneously targeting PD-1 and VEGF, exhibiting dual blockade and robust anti-tumor activity, and is positioned as a backbone immunotherapy agent[1][3][4]. The combination is under investigation in ongoing phase II studies for its ability to elicit more robust and durable anti-tumor responses through complementary mechanisms of immune modulation and targeted cytotoxicity, with a favorable safety profile reported to date[1][5][7].